A comprehensive view of inhalers / sprays / vaporizers. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Johnson & Johnson seeks FDA approval for SPRAVATO® as monotherapy for adults with treatment-resistant depression; nearly 30% of 280 million MDD patients have TRD, company cites Phase 4 study results
Published: July 22, 2024 by Johnson & Johnson Services Inc.
Johnson & Johnson seeks FDA approval for SPRAVATO® as monotherapy for treatment-resistant depression; submission based on Phase 4 data showing rapid depressive symptom improvement within 24 hours
Published: July 22, 2024 by Janssen Pharmaceutical Companies
FDA denies Orexo's OX124 nasal spray for opioid overdose for second time in 15 months; FDA requests additional technical data and human factor study results
Published: July 17, 2024 by FiercePharma
U.S. Clinical Trial: University of Nebraska Listed a New Clinical Trial to Study Theophylline Nasal Spray for PD-Related Hyposmia and Anosmia
Published: July 15, 2024 by Contify Life Science News
NIHR: Over-the-counter nasal sprays proven to keep colds and flu at bay and reduce antibiotic use
Published: July 12, 2024 by Contify Life Science News

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count